Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06168201 · ClinicalTrials.gov registry record
VIrtual STudy in Achondroplasia for the US (VISTA)
A clinical trial of Achondroplasia, sponsored by BioMarin Pharmaceutical.
- Recruiting
- Registry status
- 170
- Enrollment target
- 7
- Study locations
NCT06168201 is a study of Achondroplasia that is actively recruiting participants, run by BioMarin Pharmaceutical. The registered enrollment target is 170 participants, above the 132-participant average among 9 other Achondroplasia trials with a reported enrollment target (29% higher). The trial reports 7 study locations across 6 states.
The verdict
NCT06168201, a study of Achondroplasia, is actively recruiting participants, sponsored by BioMarin Pharmaceutical.
- RECRUITING
- Registry status
- 170 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is an observational study of individuals with achondroplasia in the United States. The primary study population consists of pediatric individuals treated and untreated with VOXZOGO™. Study enrollment started in February 2023. The projected total duration of the study is approximately 5 years at minimum from start of study recruitment in February 2023, with the duration of individual prospective follow-up differing depending on the time of enrollment. The study duration may be extended based on decisions by the study sponsor. Data will be collected in two formats for the primary pediatric study population: 1. Participant-mediated access to electronic health records(including medical imaging, when available) which will enable retrospective and prospective collection of secondary data reflecting real-life treatment use and clinical care. . 2. Primary data collection of Clinical Outcome Assessments (COAs) and questionnaire data. Data will be collected in the following format for the adult cohort: \- Participant-mediated access to electronic health records (including medical imaging, when available) which will enable retrospective and prospective collection of secondary data reflecting real-life treatment use and clinical care. The primary study population will include approximately 150 pediatric individuals with achondroplasia regardless of their treatment status with VOXZOGO™. Individuals may change status from untreated to treated during the prospective period of the study (or vice versa) however they will only be counted once, based on their treated status at the point of enrollment. The secondary study population will include 20 adolescent and adult participants.
Conditions Studied
Study Locations (7)
California
- UCSF - Oakland
- PicnicHealth - San Francisco
North Carolina
- Piedmont Health - Statesville
Ohio
- University of Cincinnati - Cincinnati
South Dakota
- Sanford Health - Sioux Falls
Texas
- Baylor College of Medicine - Houston
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2023-02-21 |
| Est. Completion | 2028-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06168201
The ClinicalTrials.gov registry entry for NCT06168201 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 132-participant average among 9 other Achondroplasia trials with a reported enrollment target (29% higher). The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Achondroplasia appearing as the primary indexed condition, and to 0 interventions.
NCT06168201 reports 7 study locations spanning 6 distinct geographic areas - top geographies include California, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT06168201 about?
NCT06168201 is a clinical study titled "VIrtual STudy in Achondroplasia for the US (VISTA)". This is an observational study of individuals with achondroplasia in the United States. The primary study population consists of pediatric individuals treated and untreated with VOXZOGO™. Study enrollment started in February 2023. The projected total duration of the study is approximately 5 years at...
What is the current status of trial NCT06168201?
This trial is currently recruiting. The enrollment target is 170 participants. The study started on 2023-02-21. Estimated completion is 2028-02.
What conditions does trial NCT06168201 study?
This clinical trial studies the following conditions: Achondroplasia.
Who is sponsoring clinical trial NCT06168201?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06168201 being conducted?
This trial has 7 study locations across California, North Carolina, Ohio, South Dakota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
RECRUITING · Phase 2
-
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
RECRUITING · Phase 2
-
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING · Phase 2
-
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.